Michael LaRosa was Jill Biden's press secretary for the first 18 months of Joe Biden's presidency, and in recent weeks he's ...

Pliant and Acelyrin adopt poison pill measures to counter activist investor Kevin Tang's stock accumulation, aiming to ...

With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...

New York, New York-- (Newsfile Corp. - March 21, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Pliant Therapeutics, Inc. ("Pliant" or ...

Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across ...

Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...

Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested ...

Pliant Therapeutics, Inc.’s PLRX share price has surged by 10.39%, which has investors questioning if this is right time to ...

March 17, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical ...

Pliant Technologies’ CrewCom CB2 Professional Wireless Intercom system “is a full-duplex, install-friendly and feature-packed solution for small to mid-level applications requiring a reliable, great ...

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “neutral” rating restated by HC Wainwright in a research ...

Pliant Therapeutics, Inc. has announced the adoption of a limited duration stockholder rights agreement aimed at protecting shareholder interests in light of recent stock accumulations.